Onida et al developed a prognostic score for patients with chronic myelomonocytic leukemia (CMML). This can be used to estimate the prognosis for the patient. The authors are from the M.D. Anderson Cancer Center in Houston.
Criteria for CMML:
(1) absolute blood monocyte count > 1,000 per µL
(2) bone marrow blasts <= 20%
(3) hematopoietic dysplasia in bone marrow
(4) percent blasts in peripheral blood < 5%
(5) absence of Auer rods in myeloid cells
Exclusionary criteria:
(1) peripheral blood blast percent >= 5%
Parameters:
(1) hemoglobin
(2) absolute lymphocyte count
(3) peripheral blood immature myeloid cells (myeloblasts, promyelocytes, myelocytes and metamyelocytes)
(4) percent blasts in the bone marrow
Parameter
Finding
Points
hemoglobin
>= 12 g/dL
0
< 12 g/dL
1
absolute lymphocyte count
<= 2,500 per µL
> 2,500 per µL
immature myeloid cells in peripheral blood
0%
>= 1%
percent blasts in the bone marrow
< 10%
>= 10%
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
• The higher the score the greater the risk and the shorter the survival.
Total Score
Risk Group
Median Survival
0 or 1
low
24 months
2
intermediate, group 1
15 months
3
intermediate, group 2
8 months
4
high
5 months
To read more or access our algorithms and calculators, please log in or register.
Purpose: To estimate the survival of a patient with CMML using the prognostic score of Onida et al (M.D. Anderson Prognostic Score, MDAPS).
Specialty: Hematology Oncology, Clinical Laboratory
Objective: severity, prognosis, stage
ICD-10: D46,
